PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the 'Company' or 'PreveCeutical'), announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology.
PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Sol-Gel N2B delivery technology. Extensive scientific research supports the provision of a steady, sustained dose of the neurotransmitter, or its precursor, to mitigate Parkinson's disease symptoms even at an advanced stage. PreveCeutical anticipates the safety and the effectiveness of the approach to be improved through avoidance of side effects stemming from systemic exposure, and a need for lower therapeutic doses due to direct brain targeting. Further information will be provided as the program is advanced.
The Sol-Gel N2B delivery platform is designed to altogether bypass the Blood Brain Barrier (BBB), potentially improving drug bioavailability while reducing dose-related side effects associated with current drug delivery methods.
The versatility of the N2B platform delivery system paves the way for delivering therapeutics to the brain without encountering the BBB and bypassing all other body compartments; these collective attributes have the potential to reduce drug dosages and side effects, improving patient compliance and clinical outcomes.
Chairman and CEO Stephen Van Deventer commented.
'PreveCeutical's business model aims to develop cost-effective, preventive and curative therapies for patients globally. Once the program has successfully infused Dopamine and/or L-Dopa into the Sol-Gel platform, with PoC demonstrated in a preclinical model, we will explore partnerships with corporations and/or organizations who specialize in the field of Parkinson's disease'.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs. For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations
[email protected]
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, 'forward-looking statements') within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as 'will', 'pro forma', 'plans', 'expects', 'may', 'should', 'budget', 'schedules', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'potential', 'proposes' or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Centurion One Capital Hosts Most Exclusive LA Summit to Date at Iconic Beverly Hills Hotel
Los Angeles, California--(Newsfile Corp. - June 11, 2025) - Centurion One Capital is proud to announce the successful conclusion of its 6th Annual LA Summit, held from June 2nd to June 5th at the legendary Beverly Hills Hotel. This year's summit marked the firm's most dynamic gathering to date, uniting a group of influential CEOs, visionary founders, global investors, and strategic partners for four days of purposeful engagement, powerful conversations, and premier hospitality. Set against the backdrop of the famed "Pink Palace," the summit featured an elevated program of high-impact networking, thought leadership, and immersive experiences designed to foster lasting relationships and spark long-term value creation. From the moment guests arrived on the red carpet to the final toast, every detail was crafted to deliver substance with style. "Each year, our goal is to raise the bar," said Kia Besharat, Executive Chairman of Centurion One Capital. "This year's guest list was our most high caliber yet, and the outcomes speak for themselves - partnerships were struck, powerful conversations took shape, and strong momentum was built in more ways than one." Event highlights included: Welcome reception on the rooftop of the Waldorf Astoria, where guests gathered for cocktails, culinary bites, and sweeping views of the city skyline. The atmosphere was refined, the service impeccable, a perfect prelude to an extraordinary week. VIP lunch at Avra Beverly Hills sponsored by ARES Capital Markets Group, where guests enjoyed Mediterranean cuisine and networking in a relaxed setting. A high-adrenaline private shooting session at The Range LA sponsored by Card One International, curated for an elite subset of participants in a high-performance, tactical setting. A private luxury suite experience at Dodger Stadium hosted by Lucosky Brookman, bringing together guests for an exciting night of networking culminating in a Dodgers win against the Mets. CEO / Founder dinner at Hotel Bel-Air hosted by Lucosky Brookman. Set in a sophisticated and serene environment, this intimate gathering brought together influential leaders for insightful dialogue, strategic connections, and a memorable dining experience in one of Los Angeles' most distinguished settings. Grand Havana Room hosted by Specialty Car Collection where guests enjoyed premium cigars and engaged in conversations over hand-crafted cocktails. Guests were also delighted by the VIP transportation that was arranged, which included a fleet of vehicles that included the iconic Ferrari F40, Lamborghini Urus, and more. A VIP finale dinner with a full buyout of The Penthouse at Mastro's Steakhouse Beverly Hills, closing the summit on a high note with an evening of live entertainment, fine dining, celebration and connection. Centurion One Capital would like to extend its sincere thanks to all guests, panelists, and sponsors who made the summit an outstanding success. Looking Ahead:Following the success of this year's event, Centurion One Capital is pleased to announce the return of its 3rd Annual Bahamas Summit, taking place at the Rosewood Baha Mar Hotel on Tuesday, October 28th and Wednesday, October 29th, 2025. More details to be announced in the coming weeks. For companies interested in presenting or for more information, please contact Shamira Kavanagh, Vice President, Operations and Events at events@ For more information about Centurion One Capital, please visit About Centurion One CapitalCenturion One Capital ("Centurion One") is the premier independent Investment Banking firm dedicated to fueling the growth and success of growth companies in North America. With an unwavering commitment to delivering comprehensive financial solutions and strategic guidance, Centurion One is a trusted strategic partner and catalyst to propel issuers to unlock their full potential. Our team comprises seasoned professionals who combine extensive financial expertise with deep knowledge of various sectors. We take a proactive and results-driven approach, working closely with our clients to develop tailored strategies and execute transactions that maximize value and drive long-term success. Centurion One - Empowering Growth. Driving Innovation. Partnering for Success. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
S2 Announces Closing of Private Placement Financing
Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - S2 Minerals Inc. (CSE: STWO) ("S2" or the "Company") announces that it has closed the previously-announced non-brokered private placement (the "Offering"). In connection with the closing of the Offering (the "Closing"), the Company sold 4,966,666 units of the Company (the "Units") at a price of $0.12 per Unit, for gross proceeds of $596,000. Each Unit consisted of one common share ("Share") of the Company and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder, on exercise, to purchase one Share until June 11, 2028, at an exercise price of $0.20 per Share. The proceeds from the Offering will be used for working capital and general corporate purposes. The securities issued pursuant to the Offering will be subject to a four-month hold period. Insiders of the Company subscribed for Units pursuant to the Offering. Participation by such insiders in the Offering was considered a "related party transaction" pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with such insiders' participation in the Offering in reliance on Sections 5.5(b) and 5.7(1)(a) of MI 61-101. A material change report in connection with the Offering will be filed less than 21 days in advance of Closing, which the Company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the Offering in an expeditious manner. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Early Warning Disclosure On June 11, 2025, in connection with the Closing, S2's Executive Chairman, Patrick Sheridan, entered into a subscription agreement pursuant to which he purchased 3,500,000 Units for an aggregate subscription price of $420,000. Prior to the Closing, Mr. Sheridan had ownership and control (together with joint actors) over an aggregate of 7,848,710 Shares (which represented approximately 41.4% of the then issued and outstanding Shares). Following the Closing, Mr. Sheridan has ownership and control (together with joint actors) over an aggregate of 11,348,710 Shares (which represents approximately 47.4% of the issued and outstanding Shares) and 3,500,000 Warrants entitling him to acquire an additional 3,500,000 Shares (which represents approximately 54.1% of the Shares on a partially diluted basis). The Shares and Warrants comprising the Units were acquired by Mr. Sheridan for investment purposes. Depending on various factors including, without limitation, the Company's financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Company's business or financial condition and other factors and conditions he deems appropriate, Mr. Sheridan may increase or decrease his beneficial ownership of Shares or other securities of the Company whether in the open market, by privately negotiated agreement or otherwise. The Company is located at 141 Adelaide Street West, Suite 1101, Toronto, Ontario, M5H 3L5. A copy of the Early Warning Report for Mr. Sheridan can be obtained by calling S2's office (416.628.5904) or c/o 141 Adelaide Street West, Suite 1101, Toronto, Ontario, M5H 3L5 or on the Company's SEDAR+ profile at About S2 Minerals Inc. S2 Minerals Inc. is a Canadian mineral exploration company focused on exploring mineral properties in Northwest Ontario, including the Sandy Lake project. The Sandy Lake project comprises approximately 167,000 acres of contiguous mineral claims in the Sandy Lake Archean Greenstone Belt, located approximately 140 miles north of Red Lake, Ontario. S2 beneficially holds a 100% interest in the mineral rights to approximately 137,000 acres, and holds a 50.1% interest in the approximately 15,000 acres of the "Weebigee Joint Venture" claims and a 50% interest in a further 15,000 acres of the Southern Block claims in joint ventures with Goldeye Explorations Limited, now part of NexGold Mining Corp. The Sandy Lake project is held within the traditional territories of Sandy Lake First Nation and Keewaywin First Nation. S2 also holds additional mineral claims which are located within Eabametoong First Nation traditional lands. It is expected that over time, S2 may add new Canadian-focused exploration stage projects to its portfolio. For further information please contact: Dan Noone CEO +1.416.628.5904 Email: info@ Forward-Looking Statements This news release contains certain forward-looking statements, including, but not limited to, statements about the Offering, including the expected use of proceeds. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. The Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit
Yahoo
2 hours ago
- Yahoo
Metalite Announces Appointment of New CFO
Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - Metalite Resources Inc. (CSE: METL) (OTC Pink: JNCCF) (FSE: D68) ("Metalite" or the "Company") is pleased to announce that its Board of Directors has appointed Mr. Kyle Appleby as Chief Financial Officer effective June 11, 2025. "We are pleased to welcome Mr. Appleby to the team," said Chris Hazelton, CEO of Metalite. "He is a highly experienced CFO with more than two decades of expertise in finance, accounting, auditing, and regulatory compliance. His leadership will be a valuable asset to the Company." Mr. Appleby has held Chief Financial Officer roles in both public and private companies and is a Chartered Professional Accountant in good standing with CPA Canada and CPA Ontario. The Company also extends its sincere thanks to Mr. Sheopaul for his contributions and wishes him continued success in his future endeavors. About Metalite Resources Inc. Metalite Resources Inc. is a Canadian junior mineral exploration issuer with a precious metals focused project in NSW, Australia. Contact Information Metalite Resources Hazelton, CEO(647) 660-8718info@ Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release, and have in no way passed upon the merits of the proposed transactions and has neither approved nor disapproved the contents of this news release. To view the source version of this press release, please visit Sign in to access your portfolio
